Table 1.
Baseline variables and clinical outcomes in subjects enrolled
| Variable | Overall (n = 115) |
|---|---|
| Age (y) | 44.6 (11.3) |
| Gender (male) | 102 (88.7%) |
| Etiology | |
| HBV-related (%) | 109 (94.8%) |
| Cirrhosis (%) | 63 (54.8%) |
| Ascites (%) | 109 (94.8%) |
| Hepatic encephalopathy (%) | 31 (27.0%) |
| Laboratory tests | |
| Red blood cell count | 3.9 (0.8) |
| Hemoglobin (g/L) | 118.7 (23.1) |
| Hematocrit (%) | 33.6 (6.7) |
| Platelet count (×109/L) | 109.6 (52.9) |
| Leucocyte count (×109/L) | 8.9 (4.3) |
| Neutrophil percentage (%) | 69.8 (11.0) |
| Lymphocyte percentage (%) | 19.1 (8.9) |
| Alanine aminotransferase (U/L) | 188.0 (60.2–622.8) |
| Aspartate aminotransferase (U/L) | 172.4 (97.0–395.5) |
| Serum bilirubin (μmol/L) | 392.1 (275.8–529.2) |
| Albumin (g/L) | 30.8 (5.1) |
| Serum creatinine (μmol/L) | 77.0 (60.5–100.5) |
| Urea nitrogen (μmol/L) | 3.8 (2.9–6.1) |
| Serum sodium (mmol/L) | 136.7 (4.7) |
| C-reactive protein (mg/L) | 11.6 (6.9–17.3) |
| International normalized ratio | 2.5 (0.8) |
| D-dimer (mg/L FEU) | 3.8 (2.9) |
| Fibrinogen (g/L) | 1.3 (0.4) |
| HBV DNA (> 20,000 IU/ml, %) | 65 (74.7%) |
| Organ failure (%) | |
| Liver | 99 (86.1%) |
| Coagulation | 43 (37.4%) |
| Brain | 12 (10.4%) |
| Kidney | 11 (9.6%) |
| Circulation | 3 (2.6%) |
| Respiration | 3 (2.6%) |
| EASL-ACLF criteria (%) | 59 (51.3%) |
| EASL-ACLF Grade (%) | |
| Grade-0 | 56 (48.7%) |
| Grade-1 | 7 (6.1%) |
| Grade-2 | 42 (36.5%) |
| Grade-3 | 10 (8.7%) |
| Prognostic scores | |
| MELD score | 27.2 (6.3) |
| MELD-Na score | 29.1 (9.0) |
| CLIF-C ACLFs | 43.0 (8.3) |
| CLIF-C ADs | 58.0 (9.9) |
| Mortality (%) | |
| 28-day | 41 (35.7%) |
| 90-day | 54 (47.0%) |